OMER - Omeros Corp Stock Price, Fair Value and News

5.21USD-0.07 (-1.33%)Market Closed

Market Summary

USD5.21-0.07

Market Closed

-1.33%

OMER Stock Price

View Fullscreen

OMER RSI Chart

OMER Valuation

Market Cap

301.9M

Price/Earnings (Trailing)

-2.49

Price/Sales (Trailing)

19.84

EV/EBITDA

-2.47

Price/Free Cashflow

-2.12

OMER Price/Sales (Trailing)

OMER Profitability

EBT Margin

-1195.99%

Return on Equity

170.05%

Return on Assets

-27.73%

Free Cashflow Yield

-47.07%

OMER Fundamentals

OMER Revenue

Revenue (TTM)

15.2M

Rev. Growth (Yr)

-13.83%

Rev. Growth (Qtr)

-0.41%

OMER Earnings

Earnings (TTM)

-121.3M

Earnings Growth (Yr)

-10.34%

Earnings Growth (Qtr)

-310.06%

Breaking Down OMER Revenue

Last 7 days

6.8%

Last 30 days

36.4%

Last 90 days

65.4%

Trailing 12 Months

19.8%

How does OMER drawdown profile look like?

OMER Financial Health

Current Ratio

4.76

Debt/Equity

-1.85

Debt/Cashflow

-1.08

OMER Investor Care

Buy Backs (1Y)

7.77%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	15.2M	0	0	0
2023	7.4M	0	11.3M	13.8M
2022	2.5M	0	3.3M	4.1M
2021	71.3M	86.6M	44.2M	1.7M
2020	113.6M	100.3M	96.6M	73.8M
2019	50.1M	75.2M	100.4M	111.8M
2018	56.1M	47.3M	38.6M	29.9M
2017	46.5M	53.6M	64.0M	64.8M
2016	20.4M	27.2M	35.2M	41.4M
2015	827.0K	4.0M	7.0M	13.5M
2014	605.0K	510.0K	528.0K	539.0K
2013	5.6M	4.2M	3.0M	1.6M
2012	4.8M	5.2M	5.6M	6.0M
2011	3.0M	3.6M	4.4M	4.5M
2010	0	1.7M	1.9M	2.1M
2009	0	0	0	1.4M

Get all data in R, Python etc through our Historical Stock Data APIs

About Omeros Corp

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that is in phase Ib clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders; and OMS405 that is in phase II clinical trials for opioid and nicotine addiction. In addition, the company develops MASP-2-small-molecule inhibitors for the treatment of aHUS, HSCT-TMA, and age-related macular degeneration; GPR174 inhibitors and chimeric antigen receptor T-Cell and adoptive T-Cell therapies for various cancers; and G protein-coupled receptors for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.

CEO	Dr. Gregory A. Demopulos M.D.
WEBSITE	omeros.com
INDUSTRY	Biotechnology
EMPLOYEES	196

Omeros Corp Frequently Asked Questions

What is the ticker symbol for Omeros Corp? What does OMER stand for in stocks?

OMER is the stock ticker symbol of Omeros Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Omeros Corp (OMER)?

As of Fri Jul 26 2024, market cap of Omeros Corp is 301.89 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of OMER stock?

You can check OMER's fair value in chart for subscribers.

Is Omeros Corp a good stock to buy?

The fair value guage provides a quick view whether OMER is over valued or under valued. Whether Omeros Corp is cheap or expensive depends on the assumptions which impact Omeros Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for OMER.

What is Omeros Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jul 26 2024, OMER's PE ratio (Price to Earnings) is -2.49 and Price to Sales (PS) ratio is 19.84. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. OMER PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Omeros Corp's stock?

In the past 10 years, Omeros Corp has provided -0.094 (multiply by 100 for percentage) rate of return.